Legal
Decriminalization, regulation, and access — where psilocybin stands under the law, who is changing it, and what it means for the path ahead.
Never Miss What Matters
One weekly email. The best psilocybin research, podcasts, and news from trusted sources around the world — no searching required.
Psilocybin for Veterans: Bill Proposes $30M in Federal Funding
The Innovative Therapies Centers of Excellence Act of 2025, a bipartisan Senate bill, would allocate $30 million per year to fund at least five VA medical facilities offering…
New Jersey’s Psilocybin Pilot: What the Law Actually Says
New Jersey has passed a bill establishing a supervised psilocybin therapy pilot program, according to a January 2026 report in Psychology Today. The legislation creates a legal framework…
Psychedelic Medicine Access: Five Federal Policy Paths
A memo submitted to the Congressional Psychedelics Advancing Therapies Caucus, authored by Reason Foundation analysts, lays out five legislative approaches that could reduce scheduling barriers, expand use of…
Psilocybin for Mental Health: Pa. Legislature Weighs Access
In September 2025, Pennsylvania House Democrats convened a policy committee hearing on a bipartisan bill that would legalize psilocybin therapy in the state, but only after federal FDA…
Minnesota Psilocybin Research Bill: What Lawmakers Approved
Minnesota state lawmakers are on the verge of approving legislation that would authorize federally funded psilocybin research. The bill does not legalize psilocybin for general use. It is…
Senate Bill S.4031: Federal Psychedelic Research at the VA
Senate Bill S.4031, the Innovative Therapies Centers of Excellence Act, would authorize the Department of Veterans Affairs to establish specialized centers studying psilocybin, MDMA, ibogaine, ketamine, and 5-MeO-DMT…
Psilocybin Access: Bipartisan Bill Targets Seriously Ill Patients
A bipartisan bill introduced in Congress would permit licensed physicians to administer Schedule I controlled substances, including psilocybin and MDMA, to patients with serious or terminal illnesses. The…
FDA Fast-Tracks Psychedelic Research: What the Order Means
The FDA announced a package of measures designed to speed up clinical research into psychedelic-based treatments for serious conditions including treatment-resistant depression, PTSD, and substance use disorders. The…
FDA REMS Framework and Psilocybin Therapy Access
A legal analysis published by Vicente LLP examines the federal pathway through which psychedelic medicines such as COMP360, a proprietary psilocybin formulation, could reach clinical use under FDA…
You've Come This Far. Stay Informed.
Join our free weekly newsletter and get the best psilocybin research, medical journals, podcasts, and news — hand-curated from trusted sources around the world and delivered straight to your inbox.